CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization.
0
CIRM-Funded Clinical Trials
Photo Credit: UCLA Broad Stem Cell Research Center
Funding Opportunities
Visit our Funding Opportunities page to apply for clinical trial research funding.
Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
---|---|---|---|---|---|---|
Age-related macular degeneration | Mark Salman Humayun | University of Southern California | Phase 1 | Closed | 16 | |
Age-related macular degeneration | Jane Stephanie Lebkowski | Regenerative Patch Technologies LLC | Phase 2 | Recruiting | N/A | |
Age-related macular degeneration | Dr. Jeffrey H Stern | Luxa Biotechnology | Phase 1/2 | Launching | N/A | |
Alpha Thalassemia Major | Dr. Tippi C. MacKenzie | University of California, San Francisco | Phase 1 | Enrolling by invitation | 10 | |
Amyotrophic Lateral Sclerosis | MD Ralph Kern | BrainStorm Cell Therapeutics | Phase 3 | Completed | 196 | |
Amyotrophic Lateral Sclerosis | Professor Clive Niels Svendsen | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 18 | |
Amyotrophic Lateral Sclerosis | Professor Clive Niels Svendsen | Cedars-Sinai Medical Center | Phase 1 | Launching | N/A | |
Anemia Bone Marrow Transplant and Viral Infection |
Alice Bertaina | Stanford University | Phase 1/2 | Launching | N/A | |
Anemia | Dr. Matthew H Porteus | Stanford University | Phase 1/2 | Launching | N/A | |
Anemia | Ryotaro Nakamura | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Arthritis Osteoarthritis |
Dr. Kristen A Johnson | Calibr | Phase 1 | Completed | 60 | |
B cell cancers Leukemia |
Thomas J Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
B cell cancers Leukemia |
Dr. David B. Miklos | Stanford University | Phase 1 | Active, not recruiting | 56 | |
B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
B cell cancers | Dr. Paul W Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Closed | 130 | |
Beta Thalassemia | Bettina Cockroft | Sangamo BioSciences, Inc. | Phase 1/2 | Completed | 5 | |
Bladder or Urinary Tract Disorder | James Yoo | Wake Forest University Health Sciences | Phase 1 | Not yet recruiting | 10 | |
Blood Cancer | Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | |
Blood Cancer | Thomas J Kipps | University of California, San Diego | Phase 1 | Completed | 26 | |
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
Blood Cancer | Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1/2 | Completed | 42 | |
Blood Disorders | Ilya Rachman MD PhD | Nexcella, Inc. | Phase 1 | Launching | N/A | |
Bone Marrow Transplant and Viral Infection | Michael A. Pulsipher | Children’s Hospital of Los Angeles | Phase 1/2 | Active, not recruiting | 60 | |
Bone or Cartilage Disease | Dr. Gayatri Rao | Rocket Pharmaceuticals, Inc. | Phase 1 | Closed | 1 | |
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes | Immusoft Corporation | Phase 1 | Launching | N/A | |
Brain Cancer | Dr. Christine E. Brown | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 82 | |
Brain Cancer | Anthony J. Gringeri | ImmunoCellular Therapeutics | Phase 3 | Suspended | 234 | |
Brain Cancer Breast Cancer |
Dr Jana Portnow | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 39 | |
Brain Cancer | Dr. Leo D Wang | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 18 | |
Brain Cancer | Crystal Mackall | Stanford University | Phase 1 | Recruiting | 54 | |
Brain Cancer | Dr Jana Portnow | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Brain Cancer | Dr. Reena Parada Thomas | Stanford University | Phase 1 | Launching | N/A | |
Brain Cancer | Dr. Hideho Okada | University of California, San Francisco | Phase 1 | Launching | N/A | |
Brain Cancer | Noriyuki Kasahara | University of California, San Francisco | Phase 1 | Launching | N/A | |
Colon Cancer | Mark Chao | Forty Seven Inc. | Phase 1/2 | Completed | 78 | |
Colon Cancer | Ivan King | Tachyon Therapeutics, Inc | Phase 1 | Launching | N/A | |
Corneal Damage | Dr. Sophie X Deng | University of California, Los Angeles | Phase 1 | Recruiting | 20 | |
Corneal Damage | R. Kim Brazzell | Combangio, Inc. | Phase 2 | Launching | N/A | |
COVID-19 Respiratory Disorders |
Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
COVID-19 | Dr. Michael Matthay MD | University of California, San Francisco | Phase 2 | Completed | 120 | |
COVID-19 Respiratory Disorders |
William van der Touw | Celularity Inc. | Phase 1/2 | Closed | 86 | |
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui | University of California, San Diego | Phase 1/2 | Active, not recruiting | 6 | |
Danon Disease Pediatrics |
Dr. Jonathan Schwartz | Rocket Pharmaceuticals, Inc. | Phase 2 | Launching | N/A | |
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer | University of California, Davis | Phase 2 | Recruiting | 55 | |
Epilepsy | Dr. Cory R Nicholas | Neurona Therapeutics | Phase 1 | Recruiting | 40 | |
Epilepsy | Dr. Cory R Nicholas | Neurona Therapeutics | Phase 1/2 | Launching | N/A | |
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B. Kohn Leslie Meltzer |
University of California, Los Angeles Orchard Therapeutics |
Phase 2 | Completed | 10 | |
Heart disease associated with Duchenne muscular dystrophy | Dr. Linda Marban | Capricor, Inc | Phase 2 | Completed | 25 | |
Heart failure | Dr. Rachel Ruckdeschel Smith | Capricor, Inc | Phase 2 | Closed | 135 | |
Heart failure | Dr. Joseph C. Wu | Stanford University | Phase 1 | Recruiting | 18 | |
Heart failure | Dr. Matthew Pollman | Tenaya Therapeutics, Inc. | Phase 1 | Launching | N/A | |
HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi | University of California, Davis | Phase 1/2 | Active, not recruiting | 11 | |
HIV/AIDS | Geoff Symonds | Calimmune, Inc. | Phase 1/2 | Completed | 13 | |
HIV/AIDS | Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 12 | |
HIV/AIDS Immune Disease |
Steven G. Deeks | University of California, San Francisco | Phase 1/2 | Recruiting | 18 | |
HIV/AIDS | Mr. Daniel Dornbusch | Excision BioTherapeutics | Phase 1 | Active, not recruiting | 6 | |
HIV/AIDS | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Huntington's Disease | Dr. Vicki Wheelock | University of California, Davis | Phase 1/2 | Completed | 29 | |
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1/2 | Recruiting | 16 | |
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk | St. Jude Children’s Research Hospital | Phase 1/2 | Suspended | 28 | |
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 | Recruiting | 40 | |
Immune Disease Leukocyte Adhesion Deficiency |
Kinnari Patel | Rocket Pharmaceuticals, Inc. | Phase 1/2 | Completed | 9 | |
Immune Disease | Dr. Jonathan Benjamin | ImmPACT-Bio, Inc. | Phase 1/2 | Launching | N/A | |
Immune Disease | Maria Grazia Roncarolo | Tr1X Inc. | Phase 1 | Launching | N/A | |
IPEX Syndrome | Dr. Rosa Bacchetta | Stanford University | Phase 1 | Recruiting | 30 | |
Kidney Disease | Dr. Jeffrey L Veale | University of California, Los Angeles | Phase 1/2 | Launching | N/A | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Active, not recruiting | 240 | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Completed | 355 | |
Kidney Failure | Robert Lowsky | Stanford University | Phase 1 | Active, not recruiting | 15 | |
Kidney Failure | Daniel Brennan | Medeor Acquisition Corp. | Phase 3 | Completed | 30 | |
Kidney Failure | Dr. Everett H. Meyer | Stanford University | Phase 1 | Recruiting | 22 | |
Leukemia, Acute Myeloid (AML) | Dr. Colleen Delaney | Nohla Therapeutics Inc. | Phase 2 | Closed | 146 | |
Leukemia, Acute Myeloid (AML) | Mark Chao | Forty Seven Inc. | Phase 1 | Closed | 258 | |
Leukemia, Acute Myeloid (AML) | Joseph Paul Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 106 | |
Leukemia, Acute Myeloid (AML) | Elizabeth Budde | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Rochelle Emery | Senti Biosciences, Inc. | Phase 1 | Launching | N/A | |
Lung Cancer | Steven M. Dubinett | University of California, Los Angeles | Phase 1 | Active, not recruiting | 24 | |
Lupus, Systemic Lupus Erythematosus (SLE) | Dr. Vaneet Sandhu | Fate Therapeutics, Inc. | Phase 1 | Launching | N/A | |
Melanoma | Robert Dillman | Caladrius Biosciences | Phase 3 | Closed | 4 | |
Melanoma Skin cancer |
Dr. Antoni Ribas MD/PhD | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Melanoma | Anusha Kalbasi | Stanford University | Phase 1 | Launching | N/A | |
Multiple Myeloma | Rajesh Belani MD | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 | |
Muscle Injury | Peter C Belafsky | University of California, Davis | Phase 1/2 | Recruiting | 62 | |
Neurological Disorders | Amit Etkin | Alto Neuroscience | Phase 2 | Launching | N/A | |
Neurological Disorders Other |
Prof. Olivia Kim-McManus | University of California, San Diego | Phase 1/2 | Launching | N/A | |
Osteoarthritis | Dr. Thomas W Chalberg Jr. | Genascence Corporation | Phase 1 | Launching | N/A | |
Osteonecrosis | Nancy E. Lane | University of California, Davis | Phase 1/2 | Completed | 58 | |
Parkinson's Disease | Krystof S. Bankiewicz | Brain Neurotherapy Bio, Inc. | Phase 1 | Active, not recruiting | 11 | |
Parkinson's Disease | Dr. Edward Wirth III | Aspen Neuroscience | Phase 1 | Launching | N/A | |
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1 | Active, not recruiting | 4 | |
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 26 | |
Retinitis Pigmentosa | Dr. Henry John Klassen | University of California, Irvine | Phase 1/2 | Completed | 28 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc. | Phase 2 | Completed | 84 | |
Retinitis Pigmentosa | Professor Clive Niels Svendsen | Cedars-Sinai Medical Center | Phase 1 | Recruiting | 16 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc. | Phase 2 | Completed | 84 | |
Retinitis Pigmentosa | Paul Bresge | Ray Therapeutics, INC | Phase 1 | Recruiting | N/A | |
Sarcoma | Theodore Scott Nowicki | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Dr Morton Cowan | University of California, San Francisco | Phase 2 | Recruiting | 25 | |
Sickle Cell Disease | Dr. De-Fu Zeng | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 3 | |
Sickle Cell Disease | Dr Pierre Caudrelier | ExCellThera Inc. | Phase 1 | Withdrawn | N/A | |
Sickle Cell Disease | David Williams | Boston Children’s Hospital | Phase 2 | Recruiting | 25 | |
Sickle Cell Disease | Mark C. Walters M.D. | University of California, San Francisco | Phase 1 | Not yet recruiting | 9 | |
Solid Tumors | Dr. Dennis J Slamon | University of California, Los Angeles | Phase 1 | Completed | 46 | |
Solid Tumors | Dr. Pamela Reilly Contag PhD | BioEclipse Therapeutics INC. | Phase 1 | Recruiting | 60 | |
Solid Tumors | Pei Wang | Eureka Therapeutics, Inc. | Phase 1/2 | Launching | N/A | |
Solid Tumors | Dr. John Le Gall | Allogene Therapeutics | Phase 1 | Launching | N/A | |
Spinal Cord Injury | Dr. Jane Stephanie Lebkowski Dr. | Geron Corporation | Phase 1 | Completed | 5 | |
Spinal Cord Injury | Francois Binette | Lineage Cell Therapeutics, Inc. | Phase 1/2 | Completed | 25 | |
Stroke | Dr. Bijan Nejadnik | SanBio, Inc. | Phase 2 | Completed | 163 | |
Stroke | Dr. Gary Steinberg | Stanford University | Phase 1 | Recruiting | 30 | |
Type 1 diabetes | Howard Foyt | ViaCyte, Inc. | Phase 1/2 | Closed | 19 | |
Type 1 diabetes | Manasi Jaiman | ViaCyte, Inc. | Phase 1/2 | Completed | 49 | |
Type 1 diabetes | Dr. William Sietsema | Caladrius Biosciences | Phase 2 | Completed | 113 | |
Type 1 diabetes | Peter Stock | University of California, San Francisco | Phase 1/2 | Recruiting | 8 |